KemPharm (NASDAQ:KMPH) Stock Price Passes Above 50 Day Moving Average of $4.75

Shares of KemPharm, Inc. (NASDAQ:KMPH – Get Rating) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $4.75 and traded as high as $6.29. KemPharm shares last traded at $6.23, with a volume of 271,110 shares traded.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on KMPH. Canaccord Genuity Group lowered their price target on shares of KemPharm from $20.00 to $19.00 in a research report on Thursday, November 10th. Cantor Fitzgerald began coverage on shares of KemPharm in a research report on Thursday, November 17th. They issued an “overweight” rating and a $20.00 price target on the stock. Finally, StockNews.com raised shares of KemPharm from a “sell” rating to a “hold” rating in a research report on Saturday, November 19th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, KemPharm currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

KemPharm Stock Performance

The stock’s fifty day moving average is $4.75 and its two-hundred day moving average is $5.35. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.10 and a current ratio of 10.10.

KemPharm (NASDAQ:KMPH – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). KemPharm had a negative net margin of 328.56% and a negative return on equity of 16.12%. The business had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $2.97 million. Research analysts expect that KemPharm, Inc. will post -0.65 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Richard W. Pascoe purchased 9,500 shares of the business’s stock in a transaction on Friday, January 13th. The stock was acquired at an average price of $5.44 per share, with a total value of $51,680.00. Following the purchase, the chief executive officer now directly owns 19,973 shares in the company, valued at $108,653.12. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.10% of the company’s stock.

Institutional Investors Weigh In On KemPharm

A number of institutional investors have recently made changes to their positions in KMPH. UBS Group AG purchased a new stake in shares of KemPharm in the 2nd quarter valued at $26,000. Invesco Ltd. purchased a new stake in shares of KemPharm in the 1st quarter valued at $51,000. Kingsview Wealth Management LLC purchased a new stake in shares of KemPharm in the 2nd quarter valued at $54,000. Atom Investors LP purchased a new stake in shares of KemPharm in the 3rd quarter valued at $88,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of KemPharm by 28.3% in the 1st quarter. JPMorgan Chase & Co. now owns 18,095 shares of the specialty pharmaceutical company’s stock valued at $91,000 after purchasing an additional 3,990 shares in the last quarter. Hedge funds and other institutional investors own 19.39% of the company’s stock.

KemPharm Company Profile

(Get Rating)

KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.